Headline
The latest stories from AHA Today.
Missouri hospitals support nearly 310,000 jobs and generate more than $27 billion for the state’s economy.
House Energy and Commerce Committee leaders today released a discussion draft of bipartisan legislation to address surprise medical bills.
Three hundred two members of the House of Representatives yesterday urged House leadership to delay for at least two years the Medicaid disproportionate share hospital cuts scheduled to take effect Oct. 1.
Eligible hospitals and critical access hospitals that did not qualify as meaningful users of certified electronic health record technology for the 2019 Medicare Promoting Interoperability Program may apply for a hardship exception to avoid the associated payment penalty.
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released today by the Campaign for Sustainable Rx Pricing.
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and plans to prevent and reduce opioid use disorder in high-risk rural counties.
As part of its efforts to promote behavioral health strategies, the AHA today released a TrendWatch report outlining the opportunities, barriers and solutions to increase access to behavioral health care.
The Food and Drug Administration last week alerted health care providers and patients that batteries in certain Medtronic implantable pacemakers and cardiac resynchronization therapy pacemakers may drain more quickly than expected without warning.
The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose remedies to the nearly 30 percent cuts to Medicare payments affecting certain hospitals that participate in the 340B Drug Pricing Program.
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a brand name biological product.